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TGF-βActivin receptor-like kinase-1 or ALK-1 is a type I cell surface receptor for the transforming growth factor-β
(TGF-β) family of proteins. The role of ALK-1 in endothelial cells biology and in angiogenesis has been thor-
oughly studied by many authors. However, it has been recently suggested a possible role of ALK-1 in cardio-
vascular homeostasis.
ALK-1 is not only expressed in endothelial cells but also in smooth muscle cells, myoﬁbroblast, hepatic stellate
cells, chondrocytes, monocytes, myoblasts, macrophages or ﬁbroblasts, but its role in these cells have not been
deeply analyzed. Due to the function of ALK-1 in these cells, this receptor plays a role in several cardiovascular
diseases. Animals with ALK-1 haploinsufﬁciency and patients with mutations in Acvrl1 (the gene that codiﬁes
for ALK-1) develop type-2 Hereditary Hemorrhagic Telangiectasia. Moreover, ALK-1 heterozygousmice develop
pulmonary hypertension. Higher levels of ALK-1 have been observed in atherosclerotic plaques, suggesting a
possible protector role of this receptor. ALK-1 deﬁciency is also related to the development of arteriovenous
malformations (AVMs). Besides, due to the ability of ALK-1 to regulate cell proliferation and migration, and to
modulate extracellularmatrix (ECM) protein expression in several cell types, ALK-1 has been nowdemonstrated
to play an important role in cardiovascular remodeling.
In this review, we would like to offer a complete vision of the role of ALK-1 in many process related to
cardiovascular homeostasis, and the involvement of this protein in the development of cardiovascular
diseases, suggesting the possibility of using the ALK-1/smad-1 pathway as a powerful therapeutic target.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The Activin receptor-like kinase-1 or ALK-1 is a type I cell surface re-
ceptor for the transforming growth factor-β (TGF-β) family of proteins.
ALK-1 interacts with four ligands: TGF-β1 and TGF-β3, in a complex
with the receptor type II (TβRII); and with Bone Morphogenetic Potein
9 (BMP-9) and BMP-10, in a complexwith the Activin Receptor type IIA
(ActRIIA) or the BMP receptor type II (BMPRII). ALK-1 activation
induces phosphorylation of Smad1/5/8 that in turn dimerizes with a
common partner Smad4, and this complex translocate to the nucleus
and directly regulates transcription of speciﬁc genes [1]. ALK-1 is
predominantly expressed in endothelial cells with a critical role in reg-
ulation of developmental and pathological angiogenesis, but also in
other types of cells [2–4]. It is implicated in the pathogenesis of the
Rendu–Osler–Weber disease also known as Hereditary Hemorrhagicand Pharmacology, University
e Unamuno; 37007 Salamanca,
).
k.
l rights reserved.Telangiectasia (HHT) in the variant 2, an autosomal dominant vascular
dysplasia linked to the loss-of- functionmutations of ALK-1. Its function
in angiogenesis is controversial, but this point is the most studied and
reviewed until now [5–7]. On the other hand, some members of the
TGF-β superfamily are also implicated in several cardiovascular syn-
dromes and there are some evidences about the implication of the
ALK-1 signaling pathway in them, but little is known about the signiﬁ-
cance of this implication.
Genetic studies in mouse have provided evidence for the involve-
ment of TGF-β in hereditary and non-hereditary cardiovascular dis-
eases. It is known its protective role in atherosclerosis [8,9],
whereas reduced availability of TGF-β has proatherogenic conse-
quences in the blood vessels wall. Hypertension, hypertrophy and
cardiac remodeling are also affected by TGF-β deregulation. It medi-
ates cardiomyocyte growth, myoﬁbroblast activation and extracellu-
lar matrix deposition during cardiac remodeling [6]. In humans, it
has been shown that some polymorphisms in TGF-β1 gene
(TGF-β1) result in increased TGF-β1 expression and correlate with
an elevation in arterial pressure [10,11]. Besides, TGF-β signaling is
up-regulated by the renin–angiotensin system [12]. It acts as a down-
stream target of angiotensin signaling mediating AngII-induced cardiac
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arterial pressure in a model of hypertensive rats [10,11]. Furthermore,
heterozygous mutations in several TGF-β receptors, such as ALK-1,
Endoglin or BMPRII have been associatedwith pulmonary hypertension
[14–16]. In spite of these evidences, little is known about the role that
each TGF-β receptor is playing in cardiovascular control. The purpose
of this review is to critically asses the role of ALK-1 in physiological
and pathophysiological conditions as well as the mechanisms involved.
Thus, we will ﬁrst present a brief overview of the TGF-β family of
cytokines.
2. The TGF-β superfamily
The TGF-β superfamily components regulate the establishment of
the body plan and tissue differentiation through their effects on cell
proliferation, differentiation and migration. More than 40 members
of the family are currently known, and they are clustered in several
subfamilies, such as TGF-βs (only TGF-β1, TGF-β2 and TGF-β3
isoforms are expressed in mammals), Bone morphogenetic proteins
(BMPs: BMP-2/BMP-4 group, BMP-5-BMP-8 group, BMP-9/BMP-10
group), Osteogenic protein-1 (OP-1) group, and Nodal group, Growth
Differentiation Factors (GDFs: GDF1-GDF3, GDF5-GDF11 and GDF15),
MIF (anti-Müllerian hormone or AMH/MIS); Activins and Inhibins.
The main components of the TGF-β superfamily and its distribution
in subfamilies are described in Table 1.
TGF-βs are secreted in an inactive form [17] and are synthetized as
precursor proteins containing LAP (latency-associated peptide). They
are maintained in this way in a multiprotein complex that involves
interaction with extracellular matrix (ECM) proteins and integrins.
However, BMPs are secreted in their active form and they are regulat-
ed by BMP antagonists, such as, Dan, Chordin, twisted gastrulation
(TWSG1) and Noggin, with differential afﬁnities for the different
BMPs [18,19].
Among all these groups of cytokines, TGF-βs and BPMs signal
through the ALK-1 receptor among others. Thus, we will present
brieﬂy the major characteristics and functions of these two subfam-
ilies (Table 2).
2.1. BMPs
Bone morphogenetic proteins (BMPs) belong to the TGF-β super-
family and were originally identiﬁed for their ability to induce ectopic
bone growth and cartilage formation [20]. BMPs regulate the tran-
scription of several genes involved in osteogenesis, neurogenesis
and ventral mesoderm speciﬁcation.
Members of the BMP family can be classiﬁed into several sub-
groups, including the BMP-2/BMP-4 subgroup, the BMP-5–BMP-8
subgroup, the GDF5 subgroup (GDF5-GDF7), the OP-1 subgroup and
the BMP-9/BMP-10 subgroup. Nodal (also known as BMP16) plays aTable 1
Chart of the mammalian TGF-β superfamily.
TGF-β Superfamily
TGF-β Subfamily
TGF-β1
TGF-β2
TGF-β3
Activins
Activin A
Activin B
Activin AB
Activin C
Activin E
Inhibins
Inhibin A
Inhibin B
Inhibin C
BMPs/GDFs/OP/Nodal
BMP-2 BMP-12 (GDF-7)
BMP-3b (GDF-10) BMP-13 (GDF-6)
BMP-4 BMP-14 (GDF-5)
BMP-5 BMP-15 (GDF-9b)
BMP-6 BMP-16 (Nodal)
BMP-7 (OP-1) GDF-1
BMP-8a (OP-2) GDF-3
BMP-8b (OP-3) GDF-8 (Myostatin)
BMP-11 (GDF-11) GDF-9
GDF-15
MIF (AMS/MIS)
Müllerian Inhibitory Substancecritical role in early stages of development for cell fate determinations
as well as in cell differentiation. Monomers of these BMPs possess
seven cysteine residues, which form three intrachain disulﬁde
bonds and one disulﬁde bond with another monomer.
BMPs bind to speciﬁc heterotetrameric complexes comprising
BMPRII, ActRIIA or ActRIIB as type II receptors, and ALK-1, ALK-2,
ALK-3 or ALK-6 as type I receptors. They bind independently to both
type I and type II receptors and this receptor complex can also contain
a type III receptor/co-receptor such as betaglycan, endoglin or Repul-
sive guidance molecules (RGM—A, B or C) [21]. BMPRII is speciﬁc re-
ceptor for BMPs while ActRIIA and ActRIIB can also be used by
Activins, Nodal and Myostatin. Apart from Endoglin and Betaglycan,
DRAGON is another BMP co-receptor that belongs to the RGM family
[22]. It directly binds to BMPs enhancing BMP signaling, but not
TGF-β, and this effect can be regulated by noggin [22]. Apart from
Noggin, there are more BMPs extracellular soluble antagonists: CAN
family (Cerberus/DAN), Chordin, twisted gastrulation (TWSG1) [23]
and Gremlin [24]. Other BMPs regulators are MGP (matrix GLA pro-
tein), Neogenin and BMPER (BMP endothelial cell precursor derived
regulator) [25,26].
BMP-9, the main actor in the ALK-1 signaling, is a secreted factor
[27]. In several experiments in vitro and in vivo, BMP-9 was found to
promote cholinergic differentiation and the synthesis of acetylcho-
line, maintaining cholinergic phenotype of differentiated cells [28],
and it is expressed in the septum and spinal cord of mouse embryos.
BMP-9 was implicated in ectopic bone growth and differentiation of
mesenchymal cells into cartilage [29,30]. Besides, BMP-9 was identi-
ﬁed as a regulator of glucose metabolism, decreasing glucose produc-
tion in cultured cells, reducing glycaemia in diabetic mice [31] and
regulating iron homeostasis [32]. BMP-9 stimulates proliferation of
non-endothelial cells such as liver tumor cells, pre-adipocytes or
myoblasts [31,33].
BMP receptors (ALK-1, ALK-2, ALK-3 and ALK-6) activate Smad1,
Smad5 and Smad8 (ALK-2 only Smad1 and 5) mainly, but they can ac-
tivate other non-Smad signaling pathway, including MAP Kinases
(ERK, JNK and p38 MAPK), PI3K/Akt and PKC signaling pathways, as
well as the Rho-GTPases.
BMP-9 binds ALK-1 with high afﬁnity (EC50 around pg/ml), in as-
sociation with BMPRII or ActRIIA [34], but in certain conditions it can
also binds to ALK-2 and ActRIIB [35]. This high afﬁnity suggests that
BMP-9 binding to its receptor might occur through different molecu-
lar interactions. ALK-1, in contrast to other type I receptors, is missing
the residue Phe85, involved in hydrophobic interactions between
classical BMPs and type I receptors [36].
BMP-10 shares a 65% homology with BMP-9 and binds to ALK-1
with lower afﬁnity than BMP-9 [34]. It is mainly expressed in heart
and it promotes the cardiomyocytes growth in vitro [37]. BMP-10
contributes to the cardiac function maintenance during gestation
and it prevents from premature activation of cardiac function [37].
On the other hand, it was described that BMP-10 can substitute
BMP-9 function in retinal vascular remodeling in BMP-9 KOmice [38].
2.2. TGF-β subfamily
The TGF-β subfamily includes 5 members (TGF-β1 to 5), being
TGF-β1, 2 and 3 characteristic of mammals [39], TGF-β4 was found
in chicken [40], while TGF-β5 is characteristic of amphibians [41].
The members of this subfamily are involved in developmental and
differentiation processes, endothelial and epithelial cells growth reg-
ulation and also immune and hematopoietic function [42]. They have
been related to an excessive extracellular matrix accumulation, lead-
ing to ﬁbrotic processes in different organs, such as kidney [43], liver
[44], skin [45], and heart [46] as well.
Traditionally, it was described that TGF-β signaling through type I
receptor ALK-5 activates Smad2/3 pathway whereas signaling
through ALK-1 activates Smad1/5 in endothelial cells, in the best
Table 2
Ligands, receptors and R-Smads in the TGF-β superfamily.
Ligand Type I receptor Type II receptor Type II receptor R-Smad
BMP-9
BMP-10
ALK-1/3/6 BMPRII, ActRIIA Endoglin Smad1/5/8
GDF-7
GDF-6
GDF-5
ALK-2/3/6 BMPRII, ActRIIA, ActRIIB Smad1/5/8
BMP-8A
BMP-8B
Smad1/5/8
BMP-5
BMP-6
BMP-7
ALK-2/3/6 BMPRII, ActRIIA,
ActRIIB
Betaglycan
Endoglin
Smad1/5/8
BMP-2
BMP-4
ALK-3/6 BMPRII RGMa,b,c
Betaglycan
Endoglin
Smad1/5/8
AMH AMHRII
TGF-β1
TGF-β3
ALK-1/ALK-5 TβRII Betaglycan
Endoglin
Smad1/5/8
Smad2/3
Activins
Myostatin/GDF8
GDF11
ALK-4 BMPRII, ActRIIA, ActRIIB Betaglycan (in Activins)
Endoglin (in Activins)
Smad2/3
BMP-16/Nodal ALK-7 BMPRII, ActRIIA, ActRIIB Smad2/3
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controls the balance between active and quiescent state of the endo-
thelium. In these cells, it has been reported that ALK-1/Smad1/5 pro-
motes endothelial proliferation and migration (activation phase of
angiogenesis), and ALK-5/Smad2/3 inhibits these processes (resolu-
tion phase of angiogenesis) [3,47]. However, there is a lot of contro-
versy in this regard, with different new points of view, in part
depending on the type of cell studied [34,48]. Thus, in order to better
understand the ALK-1 functions, we will revise the major characteris-
tics of this receptor.
3. TGF-β superfamily signaling pathways
The members of the TGF-β superfamily transduce their signals by
binding two single-pass transmembrane receptor kinases, the type I
and type II receptors, which form an active heterotetramer with ki-
nase activity. There are seven type I (ALK-1-7) and four type II
(TβRII, BMPRII, ActRIIA/B) receptors. The TGF-βs diverge from BMPs
and GDFs because they bind and assemble their type I and type II re-
ceptors in a distinct manner. The type I and type II receptors directly
contact one another in the TGF-β receptor complex, but not in the
case of BMPs, preventing other ligands from interfering with the
vital roles of TGF-βs in the cells. Besides, proteins of the TGF-β super-
family can adopt “open” forms, so the monomers are loosely packed
and held together only by the inter-chain disulﬁde bond. Several of
the TGF-β/activin structures determined to date have been found in
the open forms, but none of the BMP/GDF structures [49]. The func-
tional receptor complex regulates the activation of downstream
Smad and non-Smad pathway.
3.1. Smad family-dependent signal transduction
In vertebrates there are 8 Smads: Smad1 to Smad8. Smad2 and
Smad3 are activated through carboxy-terminal phosphorylation by
the TGF-β and Activin receptors TβRI/ALK-5 and ActRIB, whereas
Smad1, Smad5 and Smad8 are activated by ALK-1, ALK-2, BMPRIA/
ALK-3 and BMPRIB/ALK-6 in response to BMP and other ligands
[50]. Members of the Smad family are well conserved and can be clas-
siﬁed into three groups: R-Smads (receptor-associated Smads),
Co-Smads (co-operating Smads) and I-Smads (inhibitory Smads).
The phosphorylated type I receptor recruits and phosphorylates the
R-Smads (receptor-regulated Smads). The TβRII-ALK-5 complex acti-
vates Smad2 and Smad3, whereas the TβRII-ALK-1 complex activates
Smad1, Smad5 and Smad8 [51]. Activated R-Smads form heteromericcomplexes with the common partner Smad (co-Smad, Smad4 in mam-
mals) and translocate into the nucleus. Smad complexes are associated
with other DNA-binding transcription factors to regulate expression.
They achieve high afﬁnity and selectivity for the target promoters
with the appropriate binding elements [52]. Cells of different types or
exposed to different conditions express distinct collection of transcrip-
tional factors partners for Smad, and thus, the TGF-β response is linked
to the cellular context. Apart from this, it was described that TGF-β in-
duces Smad1 phosphorylation independently of the BMP type I recep-
tors (ALK-1/2/3/6) mainly in endothelial cells and myoblasts [2,4,53].
TGF-β requires the kinase activity and the L45 loop motif of the type I
TGF-β receptor, ALK-5, to stimulate the phosphorylation of Smad1
and Smad5, being this phosphorylation an essential event to the initia-
tion and promotion of TGF-β-stimulated migration in mammary epi-
thelial cells [54]. A schematic representation of the Smad-mediated
signaling pathways is shown in Fig. 1.
3.2. Negative regulation of TGF-β receptor/Smad signal transduction
Duration and intensity are important determinants for the signal-
ing speciﬁcity in the TGF-β family, and for a precise regulation, Smad
signals are negatively regulated. Induction of Smad6 and Smad7 by
BMP and TGF-β represents an auto-inhibitory feedback mechanism
for ligand-induced signaling. The Ubiquitin-proteasome-mediated
degradation controls the levels of Smads post-translationally.
Smurf1 (Smad-ubiquitination-regulatory factor 1) and Smurf2 an-
tagonize TGF-β family signaling by interacting with R-Smad and
targeting them for degradation. Smurf1 interacts with Smad1 and
Smad5, affecting BMP responses, whereas Smurf2 interacts with differ-
ent R-Smads, interfering with both BMP and TGF-β/activin signaling.
Smad4 is not subjected to ubiquitin-mediated degradation, and
sumoylation enhances stability. The proteasomal degradation also reg-
ulates the R-Smads levels after translocation into the nucleus [55].
TGF-β family receptor signaling can be also inhibited through in-
hibition of Type I and Type II receptors or the receptor complex for-
mation. In mammalian cells, the phosphatase complex of GADD34
and PP1c is recruited by Smad7 and it is able to dephosphorylate
and inactivate the TGF-β type I receptor [56]. The protein phospha-
tase PP1α is also recruited by Smad7 in endothelial cells and target
ALK-1 for dephosphorylation [57]. Furthermore, the Smad responses
can be regulated by their interaction partners by retaining them in
particular subcellular locations or affecting R-Smad/Smad4 complex
formation. Some of these interactors that avoid active signaling are
SnoN [58], Man1 [59,60], Akt [61,62] or TIF1γ [63].
Smad3
pp pp ppp ppp
Smad2
p
p
Smad4
Smad3
Smad2
Smad1
Smad5
Smad8
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Smad4Smad1
Smad5 Smad8
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PAI-1
p
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Smad4Smad1p
p
Smad4
Smad3
Smad2
Smad7
Smad6
TGF-β1
TGF-β1
BMP-9
BMP-10
ALK-5 TβRII
ALK-1
TβRII BMPRII
Endoglin
Smad5 Smad8
p
Fig. 1. Schematic representation of Smad-mediated signaling pathways. TGF-β family member elicit cellular responses by binding to a heteromeric complex of speciﬁc type I and
type II serine/threonine kinase receptors and the downstream cellular effectors, Smads. On endothelial cells, The TGF-β/ALK-5/Smad2/3 and TGF-β/ALK-1/Smad1/5/8 pathways
have opposite effects; plasminogen activator inhibitor-1 (PAI-1) is speciﬁcally induced via the TGF-β/ALK-5 pathway, but Id1 (a dominant inhibitor of basic helix-loop-helix pro-
teins) is speciﬁcally a TGF-β/ALK-1 target gene.
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controlling TGF-β signaling. A schematic representation of the mech-
anisms regulating Smad-dependent signaling is shown in Fig. 2.
3.3. Smad-independent signal transduction
Apart from Smad-mediated transcription, TGF-β activates other
cascades that either regulate Smad activation or induce responses
unrelated to smad-mediated pathways. TGF-β can also regulate path-
ways such as Erk, p38MAPK, Jun N-terminal kinase (JNK), PI3K-Akt
and Small GTPases (rhoA and Cdc42) [64,65].
It is known that TGF-β can induce phosphorylation of tyrosine resi-
dues on both type I and Type II receptors and/or on Shc (Src homology
domain 2 containing) and these phosphorylated tyrosines recruit Grb2/
Sos to activate Erk through Ras, Raf and their downstream MAPK cas-
cades [66,67]. This activation is one of the non-Smad pathways neces-
sary for TGF-β-mediated epithelial to mesenchymal transition (EMT),
a phenomenon in which cells lose cell-cell attachments and epithelial
characteristics, and acquire motile and invasive properties [68,69], and
ECM protein expression [70,71]. Erk can also inhibit R-Smads activities
through their phosphorylation [72–74].
Besides, it was described that TGF-β can activate JNK through
MKK4 and p38 MAPK through MKK3/6 in various cell types [75–79].
This cascade regulates the TGF-β/BMP-induced apoptosis [80,81]and the TGF-β-induced EMT [82]. The Rho-like GTPases (RhoA, Rac
and Cdc42) are involved in dynamic cytoskeletal organization, cell
motility and gene expression [83]. Speciﬁcally, RhoA has an important
role in TGF-β-induced EMT as well [84].
Finally, The PI3K/Akt pathway is another non-Smad pathway im-
plicated in TGF-β-induced EMT and cell survival [85,86]. The activa-
tion of this route is possibly mediated by inducing a physical
interaction between the p58 subunit of PI3K and the TβRI and II re-
ceptors [87]. The activated PI3K/Akt controls translational responses
through mTOR (mammalian target of rapamycin) and S6K, which
collaborates with the Smad-dependent transcriptional responses
during EMT [88].
4. ALK-1: protein structure and function
Activin A receptor, type II-like kinase 1 (ALK-1) is a serine-threonine
kinase predominantly expressed on endothelial cells surface and it acts
as a type I receptor for the Transforming Growth Factor-β/Bone Mor-
phogenetic Protein superfamily of ligands.
4.1. ALK-1 structure
The ALK-1 structure can be divided into four distinct regions: the
signal peptide (SP), which is removed during processing to generate
Fig. 2. General mechanism of regulation of TGF-β/Smad signaling. At the cell surface, the ligand binds the receptor complex and induces transphosphorylation of the GS segments in
the type I receptor by the type II receptor kinases. These activated type I receptors in turn phosphorylate selected Smads at C-terminal serines. The activated R-Smads then form a
complex with a Smad4 and these complexes translocate to the nucleus, where they regulate the transcription of target genes. The Inhibitory-Smads (Smad6 and Smad7) impede
R-Smad phosphorylation by type I receptor kinases. They also prevent R-Smad-Smad4 complex formation. The E3 Ubiquitin ligases (Smurf1 and 2) induce type I receptor
ubiquitination and consequent receptor degradation; they also interact with R-Smads and target them for degradation. The phosphatase complex GADD34/PP1c dephosphorylates
and inactivates the type I receptor. Man1, an integral protein of the inner nuclear membrane, sequesters R-Smads, while transcriptional Smad co-repressors such as SnoN, Ski and
TGIF are also recruited to disrupt R-Smad/Smad4 complex and interfere with the association with co-activators.
Fig. 3. Structural representation of Activin Receptor-Like kinase 1 (ALK-1). ALK-1 is a transmembrane type I receptor with serine-threonine kinase activity, whose structure can be
divide into a short extracellular domain, with the signal peptide (SP) and the cysteine rich EC domain; the intracellular domain, which contains the GS (glycine/serine-rich) domain
(172-201) at the juxtamembrane position that regulates the kinase activity, and the kinase responsible for Smad phosphorylation; and ﬁnally, the single transmembrane domain
(The scheme is not to scale).
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binding; the IC (intracellular) domain, which contains the GS (glycine/
serine-rich) domain (172–201) at the juxtamembrane position (with
an important role in regulating the kinase activity), the kinase re-
sponsible for phosphorylation of SMAD1/5/8 (202–492), and the sin-
gle transmembrane domain. ALK-1 has a high degree of similarity
with other type I receptors in the GS domain, the serine-threonine
kinase domains and in the C-terminal tail [89], with a characteristic
extracellular domain. A schematic representation of ALK-1 structure
is shown in Fig. 3.
ALK-1 is missing the residue F85, involved in the hydrophobic in-
teractions between BMPs and their type I receptors [36,90], giving a
different structural basis of binding, and maybe explaining the higher
afﬁnity of BMP-9 for ALK-1 compared with other BMPs [91].
4.2. Gene structure and splice variants
The gene encoding ALK-1 (ACVRL1) spans 15,943 bp within the
large arm of chromosome 12 (12q11–q14) and is coded on the pos-
itive strand (GeneID: 94) [92]. This gene has 10 exons, but one of
them (exon 1) is transcribed but not translated. ACVRL1 cDNA was
described ﬁrst in 1993 simultaneously by two different groups
showing a characteristic transcriptional start site (TSS) [93,94].
There are various splice variants for human and mouse ACVRL1 in
the Ensembl database (http://www.ensembl.org/Homo_sapiens/Gene/
Summary?g=ENSG00000139567;r=12:52300692-52317145) for
human and http://www.ensembl.org/Mus_musculus/Gene/Summary?
g=ENSMUSG00000000530;r=15:101128522-101145336) for mice,
but little is known about the function of the different isoforms. Two
transcripts of 2.2 and 4.9 kb have been described in humans and two
ALK-1 protein species (60 and 72–76 kDa) were detected in bone mar-
row stromal cells and in mouse tissue lysates [93,95]. Two transcripts,
4.4 and 4.9 kb, were found in equal abundance in the rat lung, whereas
in the kidney, heart and aorta the 4.9 kb transcript was the most abun-
dant, suggesting there may be tissue speciﬁc transcription mechanism
of ALK-1 [93,96].
4.3. Major sites of ALK-1 expression
In mouse embryos, ALK-1 expression is ﬁrst detected at 6.5 days
post conception, showing the highest expression at day 7.5–8.5 at
sites of vasculogenesis. Between days 9.5 and 12.5 expression is
highest in blood vessels, lung mesenchyme, in the submucosa of the
stomach and intestine and in sites of epithelial-mesenchymal interac-
tions [97]. It has also been detected in kidney, brain, gonad and adre-
nal primordial [95,97,98].
In rats, ALK-1 mRNA is most abundantly expressed in the lung, al-
though it is also detected in kidney, brain, heart, intestine, thymus,
stomach, spleen and detected in the urogenital ridge of rat embryos
[96].
In humans, ALK-1mRNAwas ﬁrstly described to be expressed in the
placenta, adipose tissue and skeletal muscle [93,95]. Its expression was
shown to be more prominent in endothelial and, to a lesser extent, vas-
cular smooth muscle cells [96], and it appears to be restricted to the ar-
teries. It is also expressed at lower levels in the lymphatic endothelial
cells. In the adult, ALK-1 exhibits preferential expression in the capil-
laries and pre-capillary arterioles of the lung [99]. The expression of
ALK-1 is up-regulated during periods of active angiogenesis, during
wound healing, tissue repair and tumor angiogenesis [100–102]. In ad-
dition to its expression in the endothelium, ALK-1 has been reported in
hepatic stellate cells and chondrocytes [103,104], cardiomyocytes [105],
monocytes [106], neural crest stem cells [107], skin ﬁbroblast [108], mi-
croglia [109] or myoblasts [4]. There is more and more evidence about
the main role of ALK-1 in the arteriovenous differentiation during de-
velopment, although there is controversy in the expression pattern
[100,110,111].In 2006, Seki et al. described an exclusive expression pattern of
ALK-1 and ALK-5 in blood vessels, suggesting that each type I receptor
had its own unique functions in vascular development. They found a
high level of ALK-5 expression in perichondria, periostea, and the mes-
enchymal layers underlying epithelia in the kidney, lung, and gallblad-
der. In blood vessels, contrasting to predominant ALK-1 expression in
arterial endothelium, ALK-5 expression was localized in the medial
and adventitial layers of blood vessels, but was undetectable in the inti-
mal layer [112].
4.4. Interactions with ligands and other proteins
ALK-1 was ﬁrstly described as an orphan receptor. Later, TGF-β1
and TGF-β3, primarily described as ligands of ALK-5, were also
shown to bind ALK-1 but only in the presence of ALK-5 [113]. ALK-1
interacts on the cell surface with TGF-β superfamily receptors includ-
ing TβRII [94,114,115], ActRII [114], ALK-5 and endoglin. Association
of ALK-1 with TβRII, ActRII and endoglin may occur in a ligand inde-
pendent manner [113,115–117], and the complex formation between
ALK-1, TβRII and ALK-5 was shown to be enhanced by TGF-β1
[94,113]. In the Table 2, we show the relationship between all the li-
gands, type I receptors, type II receptors and signaling of the TGF-β
superfamily members.
ALK-1 phosphorylates Smad-1 and -5 [2,115,118], and according
to Goumans et al. [119], this phosphorylation occurs only in the pres-
ence of TβRII. ALK-1 also binds and phosphorylates the nuclear recep-
tor liver X receptor β (LXRβ), inducing its relocalization from the
nucleus to the cytoplasm, where acts as a potent inhibitor of ALK-1-
and ALK-2-mediated transcriptional responses [120].
In 2005, Blanco et al. found that the extracellular and cytoplasmic
domains of endoglin interact with ALK-1 and potentiate TGF-β/ALK-1
signaling, while appeared to interfere with TGF-β/ALK-5 signaling
[121], whereas Brown et al. determined the structure of BMP-9
(also known as growth and differentiation factor (GDF)-2) and the re-
sults of in vitro cell-based experiments indicated that ALK-1 was the
functional receptor for BMP-9 [27].
More recently it was described that BMP-9 binds ALK-1 in associ-
ation with BMPRII or ActRIIA, and triggers Smad1/5/8 phosphoryla-
tion through ALK-1/BMPRII in endothelial cells with an EC50 around
50 pg/ml (2pM), which is a much higher afﬁnity than that for other
BMPs [122].
Lee et al. reported the identiﬁcation of CK2β, the regulatory
subunit of protein casein kinase 2 (CK2), as an enhancer of ALK-1 sig-
naling. The ALK-1/CK2β interaction involves amino acid sequences
181–199 of CK2β and 207-212 of ALK-1, and enhances Smad1/5/8
phosphorylation and ALK-1-mediated reporter activation in response
to TGF-β1 and BMP-9 treatment, acting as an important regulator of
ALK-1-mediated functions in endothelial cells [123].
As we indicated before, BMP-9 (and BMP-10 as well) were iden-
tiﬁed as speciﬁc ligands for ALK-1 [27,34,35,124], and three differ-
ent type II receptors has been suggested to be implicated in
ALK-1-mediated BMP-9/BMP-10 signaling: BMPRII, ActRIIA and
ActRIIB [27,35,124]. BMP-9 is more selective for the type II receptor
ActRIIB and BMP-10 seems to bind ActRIIB, ActRIIA and BMPRII
with similar afﬁnities, but both ligands bind their type I and II recep-
tors with almost the same kinetic and thermodynamic proﬁles [122].
The high afﬁnity of BMP-9 for ActRIIB and ALK-1 differs from other
TGF-β signaling complexes where there is a binding with one of
the receptors with low afﬁnity. Besides, ALK-1 speciﬁcity is due to a
unique receptor orientation and a special set of interfacial contacts
[122].
4.5. Regulation of activity
ALK-1 was described to be unable to directly bind TGF-β ligands
but as we indicated above, it forms a high afﬁnity heteromeric
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gand binding and ALK-1 recruitment, TβRII phosphorylates the
juxtamembrane GS domain of ALK-1 which activates the serine/
threonine kinase activity of TβRII [113,125]. Some proteins were
shown to bind and downregulate ALK-1 activity, such as FKBP12
[126,127] and the nuclear receptor liver X receptor β (LXRβ) [120]. Be-
sides, it was described that in the absence of ALK-5, signaling through
the TGF-β1/ALK-1 pathway is diminished and ALK-1-induced prolifera-
tion and migration is inhibited [113]. Endoglin has been reported to
both increase signaling through the TGF-β1/ALK-1 pathway, promoting
endothelial cell migration [117] and decrease ALK-1 signaling [128].
Santibanez et al. also reported that ALK-1 is located in endothelial
caveolae and that caveolin-1 enhances the TGF-β/ALK-1 signaling
pathway, promoting the activity of the ALK-1-speciﬁc reporters. Con-
versely, speciﬁc suppression of caveolin-1 abrogated the ALK-1 sig-
naling pathway [129].
The promoter of ACVRL1 was recently shown not containing any
TGF-β-responsive element, suggesting that its promoter activity is
not regulated by TGF-β1 as other groups indicated before [92], but
it contained a high number of GC-rich Sp1 consensus sites in endo-
thelial cells [92].
4.6. ALK-1/ALK-5 functional relationship
Smads 1 and 5 signaling, induced by ALK-1 phosphorylation, has
been observed to antagonize Smad2/3. In this way, overexpression of
ALK-1 decreases ALK-5 signaling in ECs [113]. However, overexpression
of ALK-5 increases ALK-1 signaling in ECs [113]. Inhibition of ALK-5
pathway with SB431542 decreases both ALK-5 and ALK-1 pathways in
L6E9 myoblasts, suggesting that ALK-5 is essential to ALK-1 signaling
[4]. However, it was also described a different expression pattern be-
tween ALK-1 and ALK-5 that would suggest an independent signaling
[112].
One of the factors that seem to diver TGF-β1 signaling from ALK-5
to ALK-1 pathway is endoglin. Thus, we will next review brieﬂy the
functional relationship between ALK-1 and endoglin.
4.7. ALK-1 and endoglin
Endoglin is a type I integral membrane glycoprotein, which acts as
a TGF-β correceptor, with an extracellular domain of 561 amino acids,
a hydrophobic transmembrane domain and a short cytosolic domain
[7]. It is expressed as a 180 KDa disulﬁde-linked homodimer [130],
it is highly glycosylated and possesses a ZP domain in its extracellular
region [131,132]. In human and mice, there are two alternatively
spliced isoforms, long Endoglin (L) and short Endoglin (S), with dif-
ferences in their cytoplasmatic tails in 47 and 14 amino acids, respec-
tively and a 7-residues sequence speciﬁc for human S-endoglin
[133–135]. Besides, it has been described a third form of endoglin,
the soluble endoglin or sEng, detected in plasma, serum and urine
from patients with pathologies such as preeclampsia and cancer
[7,136,137].
Endoglin forms a complex with the TGF-β type I receptor ALK-1 or
ALK-5, the type II receptors and the ligand [138,139]. However,
endoglin is able to bind BMP-9 in the absence of signaling receptors
[35], and BMP-9 seems to act through a receptor complex formed
by ALK-1, BMP receptor type II and endoglin [91]. Some studies
would support the idea of that endoglin and ALK-1 participate in a
common signaling pathway and endoglin would potentiate TGF-β/
ALK-1 signaling through a direct association of ALK-1 with the cyto-
plasmic and extracellular domain of endoglin [121].
Endoglin is highly expressed in vascular endothelial cells at sites of
active angiogenesis, during embryogenesis [140,141], in healing
wounds and inﬂammation processes [101,142], upon vascular injury
[143], and in cancer [136,144–146]. It has also been described to be
overexpressed after ischemia and reperfusion in kidney, heart orhindlimbs [102,147,148]. Its contribution in all these processes suggests
the role of endoglin in vascular development and homeostasis. Endoglin
is also expressed in several other cell types. Endoglin was found
upregulated in monocyte-macrophage transition [149], in tissues un-
dergoing ﬁbrosis such as kidney and liver [150,151], and it was also
upregulated in smooth muscle cells in human atherosclerotic plaques
[152,153]. The expression of endoglin was also demonstrated in cul-
tured human mesangial cells (HMC) [154], where it negatively regu-
lates ECM levels of collagens. Besides, mutations in both endoglin and
ALK-1 (or ACVRL1) are implicated in the generation of a vascular disease
called Rendu–Osler–Weber syndrome or HHT-1 or 2 respectively. This
autosomal dominant disorder is characterized by dysplasias, frequent ep-
istaxis, muco-cutaneus telangiectasies and arteriovenous malformations
(AVMs) in the lungs, liver, brain and gastrointestinal tract [155,156].
4.7.1. Endoglin isoforms and ALK-1 activation
Contrary to L-endoglin (the classic isoform), S-endoglin seems to
have an antiangiogenic effect [4] and to be involved in the senescence
of the endothelial cells, and the interaction with ALK-5 seems to be
stronger than with ALK-1 in these type of cells [157]. On the other
hand, an in vivo overexpression of S-endoglin appears to have the
same phenotype as L-endoglin deﬁciency, suggesting opposing effects
[157].
The soluble formof endoglin (sEng) is related to several pathologies,
such as preeclampsia and cancer [136,158,159]. It has been postulated
that the increased levels of sEng in preeclampsia are consequence of
the proteolitic action of the MT1-MMP on the membrane-bound
endoglin [160–162]. Besides, it has been postulated that sEng inhibits
TGF-β1 signaling, abolishing ALK-5 signaling-dependent responses in
ECs and the proangiogenic effect of TGF-β1 in the normal endothelium
[137]. Finally, it seems that elevated sEng plays an important role in the
generation of sporadic brain AVMs [163].
4.7.2. Role of endoglin in angiogenesis and cardiovascular homeostasis
Several studies performed in endoglin haploinsufﬁcient mice
(Eng+/−) showed delayed reperfusion after ischemia induced by femo-
ral ligation [148], defective angiogenesis after myocardial infarction in-
duced by coronary artery ligation [102], and less vascular structures
formation after Matrigel plugs implantation [148]. Jerkic et al. observed
a decreased acetylcholine-dependent vasodilation in Eng+/− mice due
to a decreased NO production as a consequence of decreased levels of
eNOS [164]. Furthermore, Toporsian et al. observed a reduced NO pro-
duction but because of an uncoupling of eNOS, associated with a
defective eNOS/Hsp90 association [165]. Studies with Eng+/+ and
Eng+/− embryonic endothelial cells indicated that endoglin promotes
EC proliferation via TGF-β/ALK-1 pathway [117], suggesting the in-
volvement of both in a common signaling pathway [121,166].
5. ALK-1 and cardiovascular homeostasis
The relationship between endothelium and smooth muscle cells is
the key of vascular homeostasis. The role of endothelium as the main
vasodilation regulator due to its effect on smooth muscle cells was
described by Furchgott and Zawaski [167]. Vascular endothelium
has the main role of secretion of several substances such as vasodila-
tors (NO, EDHF, PGE2) and vasoconstrictors (TBXA2, endothelin),
which act on the smooth muscle cells, promoting contraction or re-
laxation. Besides, it secretes hemostatics and anti-hemostatics that
act on platelets, or growth factors and inhibitors that can act on sev-
eral types of cells [168].
A role for the complex of TGF-β receptors has been described in
this context, but its role has only been reported in angiogenesis, not
in vascular tone. In this way, ALK-1 is mainly expressed in endotheli-
um, whereas ALK-5 is mainly in smooth muscle cells [112,169].
In the following paragraphs we offer a perspective of the possible
role of ALK-1 in the biology of smooth muscle cells and endothelial
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homeostasis.
5.1. ALK-1 in smooth muscle cells
In spite of the relevance of ALK-1 in endothelial cells, it was also de-
scribed that the role of ALK-1 in vascular homeostasis is not exclusively
endothelium-dependent but ALK-1 may also regulate smooth muscle
cells biology. Oh and colleagues have described that ALK-1 seems to
modulate smoothmuscle cell differentiation and recruitment [112]. Be-
sides, Yao et al. demonstrated that BMP-2 and ALK-1 induced expres-
sion of Matrix Gla-Protein (MGP) in vascular mesenchymal cells
(VMCs). These studies demonstrated that ALK-1 increases proliferation
in VMCs and also differentiation. Overexpression of ALK-1 induces ex-
pression of alpha-smooth muscle actin (SMA). Moreover, ALK-1 in-
duces ALK-5 expression that also increases the expression of α-SMA.
These authors proposed a mechanism in which TGF-β activates ALK-1,
which in turn activates ALK-5 and the consequent expression of
α-SMA (a marker of VMCs differentiation). Besides, ALK-1 increases
MGP expression as a negative feedback mechanism [170].
Later studies have demonstrated that in human aortic smooth
muscle cells (HASMC) TGF-β induces smooth muscle cell differentia-
tion (evaluated by its markers α-SMA and calponin) through Smad2/
3 and Smad1/5 pathways. ALK-1 does not participate in this phenom-
enon but ALK-5 does [171], suggesting that TGF-β1 may activate
Smad1/5 in an ALK-1-independent mechanism. For this reason, the
role of ALK-1 in smooth muscle cell differentiation is still unclear.
5.2. ALK-1 in endothelial cells: angiogenesis and vascular repair
The angiogenesis is a high regulated process that occurs in embryon-
ic and postnatal development but it can be reactivated during adult-
hood for muscle growth, post-ischemic revascularization, wound
healing, cycle-dependent vascularization of the ovaries, uterus and pla-
cental development, and under several pathological conditions, such as
tumor growth,metastasis, duringwound repair or in some cardiovascu-
lar diseases, where there is an essential component of remodeling after,
for example, myocardial infarction [172].
There is a considerable discrepancy in the literature concerning
the role of ALK-1 within endothelial cells in both angiogenesis and
vascular repair. The preponderance of evidence suggests a role for
ALK-1 in the activation phase, but we cannot rule out the possibility
of different effects of ALK-1 ligands or downstream effectors in
these types of cells.
The expression of ALK-1 in endothelial cells has been shown to in-
crease proliferation andmigration [2,47,117]. Mitchell et al. demonstrat-
ed the efﬁcacy of a chimeric protein bearing the extracellular domain of
ALK-1 in reducing vessel formation and limiting tumor volume in ex vivo
and in vivomodels, acting as a potent antiangiogenic compound capable
of reducing neovascularization [173]. Supporting this idea, in 2006, Van
Laake et al. showed impaired angiogenesis after myocardial infarction
in a model of Eng+/− mice, and they proposed that the deﬁciency of
endoglin would induce downregulation of TGF-β/ALK-1 signaling, pro-
moting inhibition of proliferation and thus, a defective ability to repair
local vessel damage placed into ischemic sites [102]. On the other
hand, Lamouille et al. demonstrated that activated ALK-1, through
Smad1/5 phosphorylation, inhibited proliferation, migration, readhesion
and spreading of cultured human microvascular endothelial cells from
dermis (HMVEC-d´s) and other tissues, suggesting its implication in the
maturation phase of angiogenesis [48] (Figs. 4 and 5).
All these results demonstrate the involvement and important role
of ALK-1 in angiogenesis, and these opposed hypothesis can be
explained by the fact that they use different cell types and contexts.
However, we hypothesize that ALK-1 may have a function in both ac-
tivation and resolution phase of angiogenesis, and now the question
is whether ALK-1 is promoting or inhibiting angiogenesis dependingon the cell type, or if ALK-1 takes part in both processes in the same
cells, promoting angiogenesis or acting as a negative regulator in a di-
rect or indirect way, depending on the ligand concentration or other
unknown regulatory factors.5.2.1. ALK-1 and BMP-9/BMP-10 in ECs
As we mentioned above, BMP-9 and BMP-10 have been identiﬁed
as functional activators of ALK-1 in endothelial cells, inducing compa-
rable effects, but BMP-10 binds to ALK-1 with lower afﬁnity and is
mainly express in the murine heart; thus, its function may be cardiac
tissue-speciﬁc [174]. BMP-9 can also bind ALK-2 in non-endothelial
cells, such as myoblast and breast tumor cells.
The implication of BMPs in angiogenesis and vascular repair
comes from the implication of mutations of BMP receptors in several
human vascular diseases. Mutations in the ENG gene or in ACVRL1
cause HHT-1 and HHT-2 respectively [155,175], as we have already
indicated. BMPRII and ACVRL1 mutations were linked to pulmonary
arterial hypertension (PAH) and SMAD8 mutation was described in
patients with idiopathic PAH [176,177]. SMAD4 gene was found to
cause a syndrome with juvenile polyposis and HHT [178]. David et
al. tried to explain the etiology of HHT as a re-activation of angiogen-
esis as consequence of a deﬁcient BMP-9/ALK-1/endoglin pathway,
leading to endothelial hyperproliferation and hypermigration and
AVM formation [91]. This hypothesis was supported by the observa-
tion in zebraﬁsh in which disruption of acvrl1 induced endothelial
hyperproliferation [179].
Following this idea, it has been reported that BMP-9 inhibits prolif-
eration and migration of Human mammary endothelial cells (HMECs)
and Bovine aortic endothelial cells (BAECs) [34,35], and that BMP-9 in-
hibits Human pulmonary artery endothelial cells (HPAEC)-induced mi-
tosis via ALK-1 and BMPRII [124]. Besides, it was demonstrated that
BMP-9 inhibits neo-angiogenesis in vivo in the mouse sponge assay
[180]. BMP-10 was also showed to inhibit proliferation and migration
of dermal human microvascular endothelial cells (HMVECs) [34]. In
conclusion, BMP-9/10 is more speciﬁc for ALK-1 than other ligands
and inhibits endothelial cell proliferation and migration. On the con-
trary, Suzuki et al. found that BMP-9 promotes vasculogenesis of allan-
toic explants of mouse embryos and induces the proliferation of in vitro
cultured mouse-embryonic-stem-cells-derived endothelial cells
(MESECs), by inducing the expression of vascular endothelial
growth factor receptor 2 and Tie 2. This BMP-9-induced prolifera-
tion was transduced via ALK-1 [181]. BMP-9 also promotes in vivo
angiogenesis in a matrigel plug assay and a model of pancreatic
cancer [5]. All this evidence suggests the important role of BMP-9
through the receptor ALK-1 in controlling angiogenesis, but once
again this role seems to be cell type-dependent, as well as depen-
dent on the environmental conditions.
Cunha et al. described a synergistic effect of BMP-9 and TGF-β,
where the combined action of both ligands improved the endothelial
cell response to angiogenic stimuli [182]. Stimulation of endothelial
cells with TGF-β and BMP-9 induces a substantial upregulation of
ALK-5 target genes, such as PAI-1 and PDGF-B, supporting a previous
report of induction of Smad2 phosphorylation upon BMP-9 stimula-
tion [183]. Cunha et al. showed that ALK-5 suppression does not in-
terfere with BMP-9/ALK-1-induced phosphorylation of Smad1/5/8 in
bovine aortic endothelial cells [182]. Besides, ALK-5 was present in
EC in vivo only in low levels, and it seemed to be mainly expressed
by perivascular cells, thereby regulating angiogenesis through a para-
crine mode of action [112,184]. This suggests that ALK-5 is relevant
for endothelial homeostasis but the codependency on ALK-1 remains
unclear.
Scharpfenecker et al. proposed that the contradictory ﬁnding
about the role of ALK-1 in angiogenesis could be explained for the
fact that ALK-1 and Endoglin are involved in both the activation and
in the resolution phase of angiogenesis, so a ﬁne balance of receptor
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Fig. 4. Classic model of angiogenesis proposed by Goumans and ten Dijke [2,3,47,113,115,117]. As ALK-1 and ALK-5 signal through different Smad proteins, it has been suggested
that the opposing activities of these type I receptors regulate angiogenesis. According to this model, TGF-β binds to TβRII and recruits ALK-5. Activated ALK-5 induces phosphor-
ylation of Smad2/3 and inhibits ECs proliferation and migration. Both ALK-5 and TβRII kinase are required for ALK-1 activation. Activated ALK-1 induces Smad1/5 phosphorylation
and stimulates ECs proliferation and migration. ALK-1 not only induces responses opposite to those of ALK-5 but also directly antagonizes ALK-5/Smad2/3. The ratio between ALK-1
and ALK-5 expression will determinate the state of the endothelium.
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the effect on angiogenesis in each process [35].
Vascular Endothelial Growth Factor (VEGF), one of the main factors
implicated in angiogenesis, is known to be regulated by somemembers
of the TGF-β superfamily and there is an evidence for a direct regulation
of VEGF expression by BMP-9/ALK-1/BMPRII. He and Chen [185] identi-
ﬁed binding sites on the VEGF promoter for the BMP-Smads. The regu-
lation of VEGF through TGF-β1/ALK-5 and BMP-9/ALK-1 signaling
pathways has been described as a highly coordinated process [183].
According to them, ALK-1 and BMP-9 would contribute to the quies-
cence of the epithelium, as David et al. had already reported [180],
and they proposed that if an angiogenic factor such as BMP-4 induces
ALK-1 expression, ALK-1 (activated by the circulating BMP-9)would in-
duce MGP, which antagonizes BMP-4 and limits the angiogenic stimu-
lus. This activated ALK-1 would also induce ALK-5 expression which
stimulates VEGF expression that promotes angiogenesis in the location
thatwas determined by the initial ALK-1 induction [183]. In conclusion,
the ﬁrst induction of ALK-1 would be contributing to the stimulation of
the angiogenesis, although its ﬁnal function is to induce its inhibition.
Larrivée et al. [186] proposed a model in endothelial cells in which
BMP-9-ALK-1 signaling activates Smad1/5/8, which induces expres-
sion of the Notch target genes HES1, HEY1 and HEY2, important tar-
gets in vascular development. ALK-1 also induces expression of
VEGFR1, reducing VEGF response and tip cell speciﬁcation. This mod-
ulation of genes would contribute to the stability and quiescence of
the endothelium. Hu-Lowe et al. [187] have reported that VEGF and
bFGF induce Smad1/5/8 phosphorylation and Id1 in HUVECs. They
demonstrated that anti-hALK-1 attenuated the VEGF and bFGF-stimulated pSmads translocation to the nucleus, describing interplay
between the VEGF/VEGFR and TGF-β/ALK-1 pathways. However,
van Meeteren et al. demonstrated that anti-hALK-1 inhibited endo-
thelial cell sprouting but did not directly interfere with VEGF signal-
ing, VEGF-induced proliferation and migration of endothelial cells.
As an explanation of the fact that BMP-9 has been described as an in-
hibitor of endothelial cell proliferation, they reported that BMP-9may
bind other receptors at higher concentrations that could have oppos-
ing effects on angiogenesis. They concluded that both VEGF-VEGFR
and the BMP-9-ALK-1 pathways are required for stimulating angio-
genesis and that it will be beneﬁcial to combine anti-angiogenesis
therapy targeting VEGF and ALK-1 to overcome resistance to the cur-
rent therapy with only the anti-VEGF treatment [188].
In conclusion, the importance of ALK-1 as a receptor implicated in
angiogenesis development does not reside only in its ability of mod-
ulating TGF-β1 action, but also because it functions as a BMP-9 recep-
tor, which is recently being considered an essential modulator in
angiogenesis. BMP-9 is implicated in endothelial cells proliferation
inhibition, a key step in angiogenesis resolution, and in EC response
to VEGF. The knowledge of BMPs mechanism of action and its rela-
tionship with ALK-1 would establish a new perspective in the re-
search ﬁeld focused on discovering new therapeutic targets.
5.3. ALK-1 and cardiovascular remodeling
The role of TGF-β in cardiovascular remodeling in the infarcted
and pressure-overloaded heart has been studied for years in several
experimental models. Overexpression of TGF-β has been reported in
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growth etc. The importance of TGF-β in this phenomenon is due to
its pleiotropic effects on all cell types involved in cardiac injury repair
and remodeling [189,190] (Fig. 6).
Other studies demonstrated that TGF-β plays an important role in
the pathogenesis of the infarcted heart due to inﬂammatory and re-
parative response modulation [191]. TGF-β plays an important role
in cardiovascular remodelling in two main lines:
1. Contributing to ﬁbrosis and matrix preservation: TGF-β has been
considered a major of the pro-ﬁbrotic cytokines that stimulates
myoﬁbroblast transdifferentiation, ECM protein expression, inhibi-
tion of MMPs and upregulation of TIMPs [192].
2. Contributing to resolution of inﬂammation: TGF-β induces macro-
phage deactivation and suppressing inﬂammatory cytokine and
chemokine expression [193].
TGF-β contributes to vascular remodeling mainly due to activation
of the Smad3 signaling pathway. Bujak et al. demonstrated that
Smad3 null mice exhibited decreased neutrophil inﬁltration, macro-
phage inﬁltration and a decreased ECM protein expression in a murine
model of reperfused myocardial infarction [191].
However, there is a major question remaining to be answered:
What is the role of the ALK-1 receptor in vascular remodeling?
Firstly, ALK-1 is known to play a role in the regulation of the ECM
protein expression and synthesis in different cell types: human
chondrocytes [104], rat myoblasts [4], scleroderma ﬁbroblasts [45],
and endothelial cells [113]. However, this role is different depending
on the cellular context. For example, in endothelial cells and humanchondrocytes, ALK-1 inhibits TGF-β/ALK-5/Smad3 inducedECMprotein
expression [104]. In scleroderma ﬁbroblasts ALK-1 and endoglin pro-
motes expression of Collagen I and CTGF [45]. These studies lead us to
suggest that ALK-1 has an important role in the regulation of ECM pro-
tein expression, but depending on the cellular context, the effects are
different.
There are no studies dealing speciﬁcally with the role of ALK-1 in
cardiac ﬁbroblasts, and for this reason it would be necessary to
study the possible relationship between ALK-1 and cardiac remodel-
ing. Nevertheless, the role of endoglin in cardiac remodeling has al-
ready been studied. In an experimental model of thoracic aortic
constriction (TAC) in endoglin heterozygous mice (Eng+/−) and
their respective controls, it has been observed that lower expression
of endoglin in Eng+/− mice reduces cardiac ﬁbrosis [46]. Thus
according to the relationship between endoglin and ALK-1 already
described (Section 4.7), ALK-1 is probably involved in cardiac ﬁbrosis.
On the other hand, little has been studied about the role of ALK-1
in inﬂammatory cell inﬁltration and resolution. ALK-1 was detected
in rat macrophages but its role in these cells has not been elucidated
[96]. After that, Sanz-Rodríguez et al. demonstrated that ALK-1 was
expressed in monocytes suggesting that ALK-1 is necessary for the
proper induction of endoglin synthesis during monocyte differentia-
tion [106]. Scharpfenecker et al. demonstrated that ALK-1 heterozy-
gosity decreases the number of CD45+ cells and macrophages
inﬁltration, in a model of kidney injury induced by radiation [194].
With this background, it would be necessary to study the role of
ALK-1 in inﬂammation and cellular inﬁltration in order to unravel
the function of ALK-1 in cardiovascular remodeling. However, the
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been more studied. ALK-5 seems to play a role in the expression of
TNF-α in monocyte-derived macrophages. Stimulation with lipo-
polysaccharide induces ALK-5 expression in these cells. Moreover,
inhibition of ALK-5 with SB-431542 leads to a decrease in TNF-α
expression [195].
Endoglin has been demonstrated to participate in inﬂammation
and cellular inﬁltration in different process: Ischaemia–reperfusion
injury [147], after radiation-induced renal ﬁbrosis [196], in models
of inﬂammation after administration of carragenate or lipopolysac-
charide [197]. Although the role of ALK-1 in these effects of endoglin
is not mentioned, it may be involved in this phenomenon as it has
been above reported that ALK-1 seems to mediate most of the actions
of endoglin.
Finally, we can suggest that ALK-1 may regulate cardiovascular re-
modeling negatively due to its role in angiogenesis. Firstly because
ALK-1 promotes endothelial cell proliferation and does not partici-
pate in the resolution phase of angiogenesis [2,113]. In a second
place, ALK-1 may regulate negatively the ECM protein synthesis in
ECs [2]. Nevertheless, the role of ALK-1 in ECM protein expression
in vascular smooth muscle cells is unclear, but most evidences sug-
gest that this process is depending mainly on ALK-5 [169]. We sug-
gest that if ALK-1 is expressed in these cells, as it has been shown
by Tang et al. [171], it could regulate negatively the process of vascu-
lar remodeling ALK-5-dependent.
5.3.1. Vascular ﬁbrosis
TGF-β has long been believed to be an important ECM regulator, and
thus to play a major role in vascular ﬁbrosis, one of the main features ofcardiovascular diseases. TGF-β increases the synthesis of collagens and ﬁ-
bronectin, reduces collagenase production and stimulates the expression
of TIMP (tissue inhibitor of metalloproteinases), leading to excessive ma-
trix accumulation [198,199]. TGF-β can also participate as a mediator in
vascular ﬁbrosis induced by other mechanisms, including Angiotensin II
(AngII) and mechanical stress [200,201]. AngII-induced ECM synthesis is
mediated by TGF-β, as suggested by Ruiz-Ortega et al. [200]. However,
AngII-mediated Smad2 activation through AT-1 receptors in VSMC was
also shown to be independent of endogenous TGF-β [202]. In mouse pri-
mary aorta, AngII activates Smad pathway via MAPK activation but inde-
pendently of TGF-β [203]. Overexpression of Smad7 inhibits the
expression of connective tissue growth factor (CTGF), ﬁbronectin and col-
lagen inVSMCs inducedbyAngII [169,202], suggesting the contributionof
the Smad pathway to this vascular ﬁbrosis.
Rodrigues-Díez et al. describes that AngII activates the Smad path-
way and the production of CTGF and PAI-1 as proﬁbrotic mediators in
a TGF-β independent manner [204]. Statins have an inhibitory effect
on the AngII/Smad pathway in rat aorta and cultures VSMCs by mod-
ulating Rho/ROCK and MAPK activation, showing a possible mecha-
nism that regulates vascular ﬁbrosis. It was described that ALK-1 is
expressed in the arterial endothelium and ALK-5 in the medial and
adventitial layers in the blood vessels [112]. As ALK-5 signals via
Smad2/3, we could think that ALK-1, via Smad1/5, would act as a neg-
ative regulator pathway in this vascular ﬁbrosis. However, we should
take into account that in other cellular context such as scleroderma ﬁ-
broblast (SSc), ALK-1/Smad1/5 promotes ECM proteins such as colla-
gen I and CTGF [45,71,205].
Several studies have also demonstrated the important role of
TGF-β in regulating the intimal thickening and the arterial
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upregulated in the neointima of rat carotid arteries after
ballon-catheter injury [206], in human primary atherosclerotic,
nonatherosclerotic and restenotic lesions [207], human coronary ar-
teries with stent restenosis [208] and porcine coronary angioplasty
injury [209]. In these sites of arterial injury, Smad proteins are
upregulated. Zeng et al. showed an increased expression of activated
Smad2 in a rabbit abdominal aortic ballon angioplasty model [210].
However, Kundi et al. demonstrated an important up-regulation of
Smad3 but not Smad2 in both medial and neointima cells in a rat ca-
rotid injury study, as well as in human restenotic lesions [211]. Be-
sides, it was observed that the use of adenovirus overexpressing
Smad7 (inhibitor of the TGF-β/Smad2/3 pathway) in a
ballon-catheter injury in rat carotid resulted in reduction in intimal
hyperplasia [212]. However, a Smad3-KOmousemodel demonstrated
increased intimal hyperplasia, and these authors proposed that en-
dogenous Smad3 played a protective role following vascular injury
[213], contrary to the vision of Smad3 as critical mediator of resteno-
sis. At this point, as ALK-1 can modulate Smad2/3 as it has been de-
scribed in other models, we suggest that ALK-1 may play a role in
this process. In fact, Sluijter et al. have demonstrated in rabbit femoral
and iliac arteries that both pathways, ALK-1/Smad1/5 and ALK-5/
Smad2/3 were activated and up-regulated after balloon injury,
suggesting that both pathways can inﬂuence each other and that the
local levels determine which pathway is dominant [214].
Recently, Garrido-Martin et al. described that, after vascular injury,
ALK-1 and endoglin but not ALK-5 are upregulated at the surface of en-
dothelial cells andmigration is stimulated. The transcriptional regulator
KLF6 induces ALK-1 expression through a synergistic cooperation with
Sp1. They postulate that ALK-1 is then induced in vSMCs through a
paracrine mechanism from the endothelium, using soluble factors
such as IL-6, and contributing to vessel stabilization and recovery [215].
In conclusion, ALK-1 seems to have a powerful regulatory role in
vascular ﬁbrosis, in the same way as it has been recently reported that
ALK-1 regulates hepatic ﬁbrosis [103], renal ﬁbrosis [196] and skin ﬁ-
brosis [45,71]. In the case of vascular ﬁbrosis, as the preponderance of
evidence indicates, ALK-1 seems to act mainly as an activator. However,
the effect of ALK-1 in the different type of cells involved in this process
should be further studied.
6. ALK-1 in cardiovascular disorders
As we already indicated, alterations of the TGF-β signaling path-
way are involved in several human pathologies including cardiovas-
cular diseases, organ ﬁbrosis, reproductive diseases, and cancer and
wound healing disorders. Although there is more and more evidence
about the implication of the TGF-β type I receptor, ALK-1, in all these
processes, little is known about the mechanisms by which ALK-1 ex-
erts its functions. Now, we present here some of the pathologies
linked to an alteration in ALK-1 structure or function.
6.1. Hereditary hemorrhagic telangiectasia (HHT)
HHT or Rendu–Osler–Weber syndrome is a genetic disorder
inherited as an autosomal dominant trait with a prevalence of approxi-
mately 1:5000 to 1:10,000. HHT is characterized by frequent epistaxis,
telangiectasias in skin and mucosa, and arteriovenous malformations
(AVMs) in liver, lung or brain. The diagnosis is on the basis of at least 3
of the 4 Curacao criteria: 1) an affected immediate familymember, 2) re-
current nosebleeds, 3)multiple telangiectasias along themucocutaneous
surface and 4) AVMs on major organs [216]. This trait involves mainly
mutations in the gene encoding Endoglin (ENG) (HHT-1), or in the
gene encoding ALK-1 (ACVRL1), in the case of HHT-2. The HHT-Juvenile
polyposis syndrome is caused by mutation in the SMAD4 gene
(MADH4) [155,175,217,218]. Other HHT loci have beenmapped to chro-
mosomes 5q (HHT-3) and 7p (HHT-4) [219,220].HHT exhibits an age-related penetrance, suggesting that haplo-
insufﬁciency for the ACVRL1 or ENG alleles is not sufﬁcient to trigger
the disease and that is required more than a somatic insult affecting
the intact allele. Removing ACVRL1 from adult mice leads to a rapid de-
velopment of multiple AVMs and associated micro-haemorrhage in
lung and GI tract, whereas AVM formation in the skin requires a
wound as a stimulus, suggesting as we already mentioned, that an an-
giogenic stimulus is required [221]. Depletion of ACVRL1 in the adult
mouse brain also leads to severe AVMs in the presence of an angiogenic
stimulus [222]. In zebraﬁsh, loss of ACVRL1 lead to AVMs dependent on
blood ﬂow [223]. All these studies suggest that pathological or develop-
mental angiogenesis is required to trigger the formation of AVMs in the
absence of ACVRL1 or Endoglin and they may require blood ﬂow to
maintain the AVM.
More than 600mutations have been reported in the HHTmutation
database (http://www.hhtmutation.org). Mutations in ACVRL1 and
ENG are distributed over the entire coding sequence. Large deletions
or duplications from single exons to the whole gene have been
reported. Mutations can also be founded in intronic splice sites of
both genes. To date, the severity of the disease has not been associat-
ed with speciﬁc mutations. Even among members of the same family
that share the same mutation the manifestations vary considerably.
We will focus our review on HHT2. Although HHT-2 is the result of
haploinsufﬁciency, the abundance of missense mutations affecting
exons 6 and 7 suggests abnormal function of certain ALK-1 proteins.
Missense mutations and short in frame deletions and insertions in
ACVRL1 often impaired propensity of the affected polypeptide to
fold to the functional conformation and/or decreased stability of
the functional conformation. Three mutants of ALK-1 ectodomain
(ALK-1EC) have been described and they are expressed in transfected
cells although they hardly reach the cell surface and do not bind
BMP-9, suggesting that alteration of the structure determined by
these mutations is probably responsible of the permanence of the
protein in the cell and of the related pathogenic phenotype [224,225].
ALK-1 mutations (HHT-2) are predominant over ENG mutations
(HHT-1) in the Spanish population [226], in agreement with previous
data from other Mediterranean populations like France and Italy
[227], but different to Northern Europe or North America, where path-
ogenicmutations in ENG aremore frequent. PAVMs and gastrointestinal
bleeding were found more frequent in HHT1 patients, whereas HAVMs
were slightlymore frequent in HHT2. The severity of symptoms, such as
the amount of epixtasis and frequency, increased in age, as HHT signs
are age-dependent [226].
HHT-2 is considered a conformational disease as the mutant protein
is non-functional because of misfolding or aggregation [228,229], and
the majority of HHT-2 mutations affect residues integral to the core
structure, where only three of them were predicted to have a direct ef-
fect in BMP-9 binding [122].
6.2. Primary pulmonary arterial hypertension (PAH)
PAH is a disease that causes an elevation in pulmonary artery
pressure, leading to progressive right failure and death. One charac-
teristic of this rare disease is the abnormal pulmonary artery angio-
genesis, including endothelial and smooth muscle cell proliferation
in small to medium-sized pulmonary arteries. Mutations of genes
coding BMPR2 and ALK-1 have been associated with PAH [230,231].
In 2012, Eyries et al. reported an ACVRL1 germinal and somatic mosa-
icism characterized by the presence of two distinct mutant alleles de-
rived from the same haplotype and responsible for HHT associated
with PAH. They identiﬁed two adjacent heterozygous deleterious mu-
tations within exon 10. Mutations occurring prior to germline segre-
gation leaded to genetic mosaicism in both somatic and germline
tissues. In early childhood of ACVRL1mutations carriers was observed
PAH with worse prognosis, compared with PAH patients carrying a
BMPR2 mutation [232].
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histopathologically indistinguishable from other hereditary forms of
PAH, whereas other patients have PAH due to pulmonary arteriove-
nous ﬁstulas. Mutations in ACVRL1 are the causative factor in these
patients. A 20% of all mutations detected in ACVRL1 are associated
with the development of PAH. In rare cases, ACVRL1 mutations
cause idiopathic PAH or hereditable PAH without HHT [233].
In PAH it was also described an up-regulation of the endothelin-1
(ET-1) system, a potent vasoconstrictor and mitogen [234], that has
been shown to regulate endothelial cell migration and angiogenesis
[235]. Castañares et al. described that TGF-β induces endothelin-1 ex-
pression preferentially through the ALK-5/Smad3 pathway, and that a
signiﬁcant portion of the anti-migratory and anti-proliferative actions
of TGF-β are mediated by the autocrine function of ET-1 on endothe-
lial cells [236]. Apart from this, BMP-9 was shown to increase ET-1
production by human lung blood microvascular endothelial cells in
a similar way to that of TGF-β1, but when both are given together,
they further increased ET-1 levels [237]. Besides, BMP-9 not only in-
duced a potent phosphorylation of Smad1/5 through ALK-1 receptor,
but also induced Smad2 phosphorylation equivalent to that induced
by TGF-β. However, Park et al. in 2012, provided evidence that
BMP-9 stimulated ET-1 release in HPAECs mediated by both Smad1
and P38 MAPK, but independent of the canonical Smad4 pathway
and that ET-1 release was only partially mediated through BMPRII
and ALK-1 [238]. BMPRII dysfunction appeared important in regulat-
ing basal ET-1 levels and therefore, in the pathogenesis of PAH. More
recently, Star et al. described that BMP-7 is able to increase Smad1/5
phosphorylation and ET-1 levels through ALK-2 in a model of BMPRII
KO, with no effect in the ET-1 levels stimulated by TGF-β, suggesting
an imbalance in the BMP and TGF-β system under the origin of the
PAH [239].
In 2011, Jerkic et al. reported that adult ALK-1 heterozygous mice
develop signiﬁcant signs of PAH by 9 weeks of age, including increase
in right ventricular systolic pressure accompanied by right ventricular
hypertrophy and muscularization of peripheral arteries, and more oc-
cluded vessels and pulmonary vascular remodeling at 36 weeks, indi-
cating disease progression. These mice had higher ROS levels in adult
lungs contributing to PAH development. However, levels of NADPH
oxidases and superoxide dismutases were similar compare to adult
control mice, and the cyclooxygenase pathway was not affected. In
contrast, NO production was reduced while endothelial NO–synthase
dependent ROS production was increased in the adult heterozygous
mice, inducing changes in vasomotor tone in these mice [16].
6.3. Atherosclerosis
It is known that endoglin is overexpressed is smooth muscle cells
of atherosclerotic plaques, suggesting a role of this protein (and in
turn, of ALK-1) in atherogenesis and plaque progression [153]. MGA,
a small gamma-carboxilated protein that binds and inhibits BMP-2
and BMP-4, is considered to be an inhibitor of cardiovascular calciﬁca-
tion based on the extensive arterial calciﬁcation observed in MGP
mull mice [240]. According to Sinha et al. ALK-1 activation enhances
cell proliferation, smooth muscle cells (SMC) differentiation and ex-
pression of ALK-5, associated with SMC differentiation [241]. Func-
tional MGP requires intact α-carboxylation (vitamin k-dependent)
and when it is insufﬁcient, results in undercarboxylated MGP, which
has been detected in atherosclerotic plaques, and it is incapable of
binding BMP-2. Uninhibited BMP-2 may explain the calciﬁcation
and the osteogenic differentiation seen in atherosclerotic plaques as
well as the high levels of ALK-1 observed in these plaques [170].
On the other hand, HDLs have a well-know antiatherogenic role,
and multiple antithrombotic and anti-inﬂammatory effects. BMP-2
and BMP-4 have been identiﬁed as genes mediating the response to
inﬂammation and to oscillatory shear stress. Noggin and MGP are
able to inhibit BMPs and are also induced by oscillatory shear stress,suggesting that the balance of BMP signalling is essential in the vascu-
lar endothelium. Yao et al. (2008) demonstrated that HDL promotes
expression of ALK-2 in ECs, which mediates the increased expression
of ALK-1, VEGF and MGP, essential for endothelial cell survival and
prevention of vascular calciﬁcation, respectively [242].
Although the role of the BMP-receptors remains unclear in athero-
genesis, the fact that on the one hand, increasing concentrations of
HDL (antiatherogenic) enhances expression of ALK-2 and, in turn,
ALK-1; and on the other hand, high levels of ALK-1 were found in ath-
erosclerotic plaques, suggest that the expression of ALK-1may be a pro-
tective mechanism (if ALK-1 regulates negatively this phenomenon);
thus, it could be proposed as a possible target in the antiatherogenic
therapy and for the vascular calciﬁcation prevention.
6.4. Arteriovenous marformations (AVMs)
AVMs refer to a vascular anomaly where arteries and veins are di-
rectly connected by one or more ﬁstulas (abnormal communications)
instead of a normal capillary network. AVMs manifest as tortuous
rupture-prone vessels through which gas and nutrients exchange is
impaired. It can be found in the brain, spinal cord, lung and visceral
organs such as liver, gastrointestinal tract and spleen. Most people
with an AVM do not develop any symptoms, but about 12% of those
affected may develop signiﬁcant symptoms. Presence of AVMs is
one of the main characteristic of HHT.
In brain AVMs, which can cause intracranial hemorrhage, especially
in young people, abnormal expression patterns for proteins related to
angiogenesis (VEGF, ang2, metalloproteinase…) and inﬂammation
(IL-6, myeloperoxidase) were found. Pawlikowska et al. described a
common polymorphism in ALK-1 (ALK-1 IVS3-35A) associatedwith spo-
radic BAVM, and this associationwas strengthened in patientswhowere
also homozygous for the ENG 207G, which exhibited on its own a trend
with BAVM [243]. The interaction between multiple genetic and envi-
ronmental factors may play a role in sporadic BAVMs. According to
Kim et al. after a damaging event, inﬂammatory and angiogenic activity
initiates microvascular growth and remodeling, which are stabilized
through interplay of pathways like TIE2/ANG and ALK-1/Endoglin [244].
Using the dorsal skinfold window chamber system, Park et al. pro-
vided evidence that wounding is a second hit essential for the novo
AVM in ALK-1-deﬁcient subdermal vasculatures in adult stages. The
wound-induced de novo AVM formation involves active extension of
arterial blood vessels, which meet with growing venous branches to
form the novo AVM [221]. These authors supported these results in
the previous observation in which ALK-1 signalling inhibited
TGF-β-induced VEGF expression in ECs [183] and the description of
BMP-9 as inhibitor of angiogenic activities of VEGF and bFGF in vitro
and in vivo assays [35,180]. Besides, it was shown that VEGF levels
were elevated in the skin telangiectasia lesions of HHT patients
[245,246]. Furthermore, antiangiogenic drugs, such as thalidomide
and bevacizumab (anti-VEGF antibody) have shown to be effective
in treating GI bleeding and liver AVMs.
On the other hand, loss of ALK-1 function in zebraﬁsh embryos re-
sults in lethal AVMs that develop in a precise spatiotemporal pattern
[223]. Working with ALK-1 mutants (Alk-1−/−), Corti et al. proposed
the idea that AVMs in Alk-1 mutants represent a normal adaptive re-
sponse to increased blood ﬂow [223]. According to Hao et al. in
Alk-1+/− mice, vasodilation leading to increased tissue perfusion en-
hances cerebral capillary dysplasia during VEGF-induced angiogene-
sis, what supports the idea of interaction between genetics and ﬂow
in HHT expressivity [247]. These authors propose that the presence
of ﬂow stimulates enlargement of these vessels as a mechanism to
normalize hemodynamic forces, and thus, the transient arteriovenous
connections develop into large shunts or AVMs. It should be noted
that blood ﬂow would play a role in ALK-1 expression, as ALK-1 is
not expressed in zebraﬁsh embryos in the absence of blood ﬂow
[223].
Table 3
Drugs with inhibitory actions against ALK-1.
Type of substance Drug name Target Clinical trial Study
Human anti-ALK-1 mAb PFO3446962 ALK-1 Phase I trial Advanced solid tumors
(NT00557856)
ALK-1 Fc fusion protein RAP-041 ALK-1 Phase I trial Advanced solid tumors/
refractory multiple myeloma
Dorsomorphin or
LDN-193189
BMP signaling from ALK-1/2/3/
6 and blocks BMP-induced Smad1/5/
8 phosphorylation
Preclinical study
Herbal compound Compound 861 ALK-1 expression Cultured hepatic stellate cells
c-Abl and c-Kit inhibitor Imatinib mesylate c-Abl and Smad1 Gleevec® Dermal ﬁbrosis
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development of AVMs and that MGP deﬁciency is a major determi-
nant of both pulmonary and renal vascularization, including the for-
mation of a normal capillary networks and the number of glomeruli.
They showed that both Mgp−/− and ALK-1+/− had low MGP levels,
even though Mgp−/− mice had increased ALK-1 levels. They hypoth-
esized that in ALK-1+/− mice, low ALK-1 levels causes a deregulated
increase of VEGF through an unknown mechanism but suppresses
MGP, whereas in Mgp−/− mice, the absence of MGP allows BMP-4
to stimulate ALK-1 expression, which will promote VEGF expression
through an induction of ALK-5/TGF-β1 signaling [248].
7. Conclusions and potential therapeutic uses
We have above reported multiple evidences on the involvement of
signaling through the ALK-1/Smad-1 pathway on many physiological
and pathological processes. However, much work is needed to
completely understand the molecular mechanisms that underlie the
role of ALK-1/Smad-1 pathway in the cardiovascular homeostasis
and the precise alterations in this pathway that leads to cardiovascu-
lar diseases.
As we have described, the role of ALK-1 in cardiovascular homeo-
stasis is not only due to its important role in endothelium biology.
ALK-1 regulates vSMCs biology and its implication in arterial pressure
should be further studied. In the same manner, the role of ALK-1 in
inﬂammatory cells seems to be signiﬁcant. Firstly, there are some
data suggesting that ALK-1 might regulate inﬂammatory cell inﬁltra-
tion. Besides, ALK-1 expression during monocyte activation seems to
be related to the expression of endoglin, and endoglin plays a key role
in inﬂammatory cells adhesion and transmigration. On the other
hand, ALK-1 role in ﬁbrotic and remodeling process has been scarcely
studied, and these phenomena could contribute to other important
cardiovascular pathologies. The knowledge of ALK-1 functions in ﬁ-
brosis is just beginning: some data reveal a relationship between
ALK-1 and hepatic ﬁbrosis, and also between ALK-1 and scleroderma.
However, there are no data about the role of ALK-1 in some cardiac
cells such as ﬁbroblasts and cardiomyocytes. Therefore, we have de-
scribed numerous possible functions of ALK-1 in different cell types
in which ALK-1 is expressed: ECs, vSMCs, monocytes, macrophages
and ﬁbroblasts. These functions, sometimes opposite, are due to the
pleiotropic effect of TGF-β.
The knowledge of the mechanisms by which this signaling pathway
regulates vascular homeostasis could be useful to be able to design possi-
ble therapeutic approaches of activation or inhibition of this type I recep-
tor. There are several ALK-1 inhibitors used against tumor progression in
cancer because of its regulator role in tumor angiogenesis. In that way,
PF-3446962 and ACE-041 are drugs that block BMP-9/BMP-10 signaling
through ALK-1 [5,182]. The PF-3446962 inhibitor (anti-human ALK-1)
was recently shown to inhibit BMP-9-induced sprouts formation
[5,182]. It has also been demonstrated that BAMBI (BMP and Activin re-
ceptor Membrane Bound Inhibitor),a pseudoreceptor that forms a com-
plex with TβRI/ALK-5 and inhibits Smad3 and Smad2 phosphorylation
[249], protects the heart from biochemical stress induced by pressureoverload due to the inhibition of TGF-β signaling. BAMBI inhibition of
TGF-β function, through its receptors ALK-1, could be a powerful strategy
in order to modulate cardiovascular remodeling and angiogenesis
(Table 3).
Another potential therapeutic possibility is the use of BMPs to
stimulate ALK-1/Smad1 pathways in an effort to deal with patholo-
gies in which deﬁcient angiogenesis is present (in the cases in
which ALK-1 is activating angiogenesis), or diseases such as PAH, in
which ALK-1 deﬁciency causes increased ET-1 synthesis and release
and as consequence, the appearance of elevated pulmonary arterial
pressure. Following this idea, as we mentioned in point 6.3, stimula-
tion of ALK-1 could also prevent from atherosclerotic plaques forma-
tion. Besides, ALK-1 inhibition could be an approach in the treatment
of diseases with excessive ﬁbrosis, in the tissues where ALK-1 stimu-
lates ECM proteins expression induced by TGF-β1.
Therefore, the use of ALK-1modulators could be extended to cardio-
vascular therapy ﬁeld. However, it is needed to take into account that
ALK-1modulation could have adverse effects due to its activity in differ-
ent mechanisms in particular tissues. Since ALK-1 signaling seems to be
necessary for correct angiogenesis, the use of ALK-1 inhibitors could
prevent from normal angiogenesis and wound-healing. Furthermore,
given that impaired ALK-1 signaling is linked toHHT-2, ALK-1 inhibition
activity may induce apparition of haemorrhages or arteriovenous
malformations after tissue lesions, altering the hemodynamic status of
the organism. On the other hand, ALK-1 overexpression could trigger
pathological processes such as ﬁbrosis in several tissues.
In conclusion, we need to go in depth in the role of ALK-1 in vas-
cular homeostasis and its involvement in the genesis of vascular pa-
thologies in order to target this signaling pathway in a more speciﬁc
way.
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